Chair's Opening Remarks
Keynote Opening Address: The impact of vaccine legislation on public health in California
- What are the key drivers of hesitancy to vaccinate?
- Complacency, convenience and confidence
- What works in tackling misinformation and building trust?
- E.g. what steps are being taken to counteract sophisticated social media campaigns of parent groups?
- What responsibility do public health and education authorities have and how can companies get involved?
How T cells control antibody responses: T follicular helper (Tfh) CD4 T cells and germinal center B cell responses to vaccines
- Progress in the development of antibody drug conjugates,bispecific antibodies, and fusion protein/antibodies
- Novel approaches in antibody therapy- who is leading the next generation of antibody development?
- What have been the most successful and least successful antibody therapies? Why?
- How do we decide what level of toxicity is acceptable? Does this vary across indications?
Morning Networking Break & Poster Session
- How can innovative trial design help speed the development process and make it more accurate?
- Using one trial to address and identify the benefitting patient subpopulation
- Advanced clinical development of a plant-derived quadrivalent VLP vaccine in adults and the elderly
- Overview of umbrella trials
- What are the advantages of using this type trial design?
- Reduction of cost, patient access, accelerated development
- Efforts to create an immunotherapy clinical trial platform within the trial design to allow for running of multiple studies at the same time.
- Clinical challenges in cancer immunotherapy.
- Personalized cancer vaccines have the potential to enhance the efficacy of checkpoint inhibitors but predicting them from somatic mutations is a formidable challenge
- Overview of approach to build better vaccine cocktails.
- Understand integrated genomics and cell-based solutions in the cancer immunotherapy space, including application of whole transcriptome analysis to characterize the tumor microenvironment and biomarker discovery approaches to predict patient response.
- Immunomic is addressing the challenges in I-O by applying our proven UNITE technology platform
- LAMP-based nucleic acid immunotherapies have the potential to broaden the current use of cancer immunotherapy by complementing approved and investigational approaches.
- LAMP-based nucleic acid immunotherapy has potential as cancer immunotherapy in two general ways:
- Activation of the immune system against highly immunogenic tumor types, potentially amplifying the response seen with checkpoint inhibitors
- Creation of a new, robust immune response to tumor types that don’t otherwise provoke an immune reaction, by reconfiguring a critical component of our immune system
- Several discovery stage programs for virally driven cancers including MCC, NPC/Gastric and HCC. INDs to be filed for these programs in 2019.
Dr Maurizio Zanetti, Professor of Medicine Moores Cancer Center, University of California San Diego
Networking Lunch & Poster Session
Lunchtime presentation & book signing: “Vaccines did not cause Rachel’s Autism”
- Why we need aB. pertussisvaccine that induces potentmucosal immunity
- Relationship between colonizing nasopharyngeal infection and disease
- Mechanism of action for a live attenuated intranasal vaccine
- Non-human primate challenge model data
- Clinical study results
- Development of vaccine platform from concept to delivery
- Bioinformatic immunogen design, use of long peptides and heat shock proteins
- Challenges of working with peptides
- Selecting the correct mutations in each patient
- Parallel approach to selecting neoantigens represented by abnormal post-translational modifications
- Potential for combination therapy
- During the 20th century, B. pertussis was extensively studied in animal model systems and many “toxins” and protective antigens were described.
- DTaP vaccines were developed and put into general use in the USA in 1997.
- During the last 13 years, major pertussis epidemics have occurred in the USA due to deficiencies in DTaP vaccines.
- Two of the deficiencies are the small number of antigens and the type of cellular immune response.
- The small number of antigens leads to linked-epitope suppression.
- Because of linked-epitope suppression, all children who were primed by DTaP vaccines will be more susceptible to pertussis throughout their lifetimes.
- Pre-clinical data: observations to support immune mediated mechanism of action
- Phase 1 data in recurrent high-grade glioma: durable complete responses seen in dose escalation studies
- Clinical Development: Food and Drug Administration Breakthrough Therapy Designation, European Medicines Agency’s PRIME designation and Phase 3 trial in recurrent glioblastoma and anaplastic astrocytoma
- Updates in studies for solid tumors
- Trends in chikungunya epidemiology
- VLP vaccine technology
- Updates in phase 2 clinical trials
- Phase 3 trial protocol
- Plans for getting to the market
Afternoon Networking Break
- What is the current landscape for dengue, zika and other arbovirus vaccines?
- Which other arboviruses should be prioritized for vaccine development or for improvements of the existing vaccine(s)?
- What might emerging arboviruses look like and what improvements are needed in current vaccines?
- Finding a better way to evaluate these vaccines before going into phase 3 trials.
- Using human protection models to discover the keys to eliciting a protective immune response
- How will the immune response to one virus affect that of another?
- What are the challenges to funding and commercializing arbovirus vaccines?
- General strategies for CAR-T cell control
- Defining small molecule vs antibody-based targeting – why we use Ab-based targeting.
- Deep dive into the technicalities of designing these switches to control different targets
- Universality of the platform and potential for use in solid tumors.
- A TB vaccine is urgently needed to meet the WHO and UN goals for ending TB
- Update on status of the overall pipeline of TB vaccine candidates
- Substantial progress was demonstrated by the results of two efficacy trials of vaccine candidates
- Implications of the efficacy trial results and takeaways for future candidates and trials
- Vaccine development for CMV: High unmet medical need
- CMV vaccine development at GSK, past and present
- Critical challenges facing CMV vaccine developers
Chair closing remarks of day one followed by onsite networking drinks reception and meet & greet with key speakers
last published: 22/Nov/18 11:45 GMT